Four Questions That Defined a $1 Billion Deal with Robert Lovegrove
Release Date: 02/26/2026
M&A Science
Most consumer brand founders think about exit as an event. Keith Levy thinks about it as a design requirement. In the second of two episodes, Keith walks through what exit-ready actually looks like in CPG: the revenue and EBITDA thresholds that matter, why you have to get beyond the corp dev team to the operators who actually need what you're building, how capital gets wasted at every stage of a brand's lifecycle, and what the investments that produce exits have in common versus the ones that don't. If you missed the first episode, it covers Keith's five-pillar CPG diligence framework and the...
info_outlineM&A Science
Keith Levy backed an exit of just under $1B and a $400M exit using the same five-pillar framework, and he starts with the founder every time. Finance comes last. As Operating Partner at Sonoma Brands Capital, Keith has spent six years evaluating consumer brands across food, beverage, pet food, snacks, and cosmetics. Before that he was CMO at Anheuser-Busch through the $52B InBev deal, president of Royal Canin USA for Mars, and the strategic acquirer who led the Kind acquisition at Mars Wrigley. He knows what the data room doesn't show you, and this conversation is built around that gap....
info_outlineM&A Science
Roll-up platforms that skipped real integration are getting exposed when they go to market. Buyers want proof of organic growth, clean data, and a platform that actually functions as one. A lot of processes are breaking down because those proof points aren't there. Matt James co-founded Oakbridge Insurance in 2020 and has since closed 60+ acquisitions, integrating 100% from day of close. This conversation covers how he built that system, what went wrong with billion-dollar competitors, and what he would fix first if he walked into a revenue-aggregating roll-up right now. What You'll...
info_outlineM&A Science
This is Part 2 of our conversation with Dan Caruso, founder and former CEO of Zayo Group. Be sure to start with Part 1. It covers the Zayo thesis, deal sourcing, structure, and the negotiation playbook, whereas this episode picks up at the execution. Part 2 is about the equity value-creation framework Dan built at Zayo, applying the same IRR math PE firms use for their portfolio companies to daily operating decisions. It replaced budgets and tied every compensation decision to a single equation. It ends with the exit and how Dan put together a competing bid after a buyer consortium locked up...
info_outlineM&A Science
Dan Caruso built Zayo from a startup into a $14B+ bandwidth infrastructure platform through 45 acquisitions. In Part 1, he walks through the full buyer-led playbook: how the thesis was built on a contrarian bet that everyone else got wrong, how proprietary deals were sourced through early relationship-building, and why fast integration wasn't a reputation problem — it was a competitive advantage. He also breaks down the metric trap most roll-up operators fall into: mistaking EBITDA growth for true value creation. If your board is tracking acquisitions individually or your deal...
info_outlineM&A Science
Most US buyers approach Latin America M&A the same way they do a domestic deal — optimize the process, close fast, move on. That approach gets deals killed. Rodrigo Dominguez Sotomayor, Partner at White & Case LLP, has spent 25 years closing transactions across every major Latin America market. In this episode, he walks through what actually determines outcomes: antitrust consent timelines, labor regimes that make post-close restructuring expensive, and the relationship dynamics that can unwind a billion-dollar deal a week before signing. What You’ll Learn In This Episode: ...
info_outlineM&A Science
Booz Allen Hamilton didn't build one of the most active acquisition programs in federal tech by waiting for banker inbounds. They built it by showing up years before anyone else. Chrissy Cox has built Booz Allen's corporate development function from scratch and done it twice. Her team was named Deal Team of the Year by the Association for Corporate Growth, and under her leadership, roughly 80% of their acquisitions come from companies they already have a relationship with. That's not luck, it's a system. In this episode, she breaks down exactly how that system works — from pipeline...
info_outlineM&A Science
Salas O'Brien has completed 30+ mergers with a 100% success rate and 93% cumulative leadership retention. That doesn't happen by accident. Nathan Rust, Senior VP of Corp Dev, explains the system behind those numbers. He shares how they screen bad fits on the first call, why their CEO meets every employee from acquired firms, and how a founder-driven sourcing flywheel attracts inbound deals. In this episode: You’ll learn how they screen 200+ opportunities a year down to the ones worth closing, why their initial diligence list is 10 questions, how reverse due diligence works as a real...
info_outlineM&A Science
Italy remains one of Europe’s most attractive markets for foreign investment. But cross-border deals in Italy are shaped by regulatory scrutiny, strict labor laws, and unique cultural dynamics that many investors underestimate. In this episode, Mauro Sambati and Donato Romano, Partners at Gianni & Origoni, explain what it truly takes to structure and close successful transactions in Italy. What You’ll Learn in This Episode Why Golden Power must be structured as a condition precedent before closing How strict Italian labor laws impact asset deals and post-closing restructuring...
info_outlineM&A Science
When it comes to billion-dollar deals, success depends less on how much analysis is done and more on how clearly the organization aligns around what truly matters. In this episode of the M&A Science Podcast, Robert Lovegrove, President & CEO of The ChemQuest Group. Previously, as VP of Corporate Strategy at Milliken & Company, shares how one of the company’s largest acquisitions was shaped by focus, discipline, and internal alignment. Rather than overwhelming the process with more diligence, leadership centered the decision around four core questions that clarified risk, built...
info_outlineWhen it comes to billion-dollar deals, success depends less on how much analysis is done and more on how clearly the organization aligns around what truly matters.
In this episode of the M&A Science Podcast, Robert Lovegrove, President & CEO of The ChemQuest Group. Previously, as VP of Corporate Strategy at Milliken & Company, shares how one of the company’s largest acquisitions was shaped by focus, discipline, and internal alignment. Rather than overwhelming the process with more diligence, leadership centered the decision around four core questions that clarified risk, built conviction, and guided a confident go / no-go decision.
Robert also explains how adjacency-based M&A reduced execution risk, why trust mattered more than price in winning the deal, and how treating culture as a deal consideration—rather than an integration afterthought—helped unlock long-term growth.
What You’ll Learn in This Episode
- How to create executive alignment in high-stakes M&A decisions
- The four questions that anchor go / no-go decisions at scale
- Why adjacency-driven M&A improves confidence and execution
- How trust can outweigh price in competitive deal processes
- Why culture should be treated as a deal risk, not an HR issue
This episode offers a practical perspective for M&A leaders navigating complex decisions where clarity and conviction matter as much as valuation.
Listen to the full episode to learn how strategic focus can define billion-dollar outcomes.
_____________________
This episode is brought to you by the M&A Science Intelligence Hub.
You know that feeling when you're deep in a deal and something doesn't sit right, but you've already invested weeks into it? The Intelligence Hub helps you think like someone who's walked away from bad deals before — because they have. Pattern recognition from 400+ practitioner interviews, with citations back to the exact conversation. Join the professional membership at mascience.com/membership.
_____________________
This episode is also sponsored by DealRoom
Stop juggling six different tools to run one deal. DealRoom brings pipeline management, diligence tracking, document sharing, and team collaboration into one platform. Purpose-built for M&A teams who need to move fast without losing control.
Request your demo today:https://hubs.ly/Q03ZMvQX0
____________________
Episode Chapters
[00:04:24] From Engineer to Strategy Chief – Robert Lovegrove’s path from mechanical engineer to VP of Corporate Strategy at a 160-year-old family-owned industrial.
[00:05:23] Designing for Dividends – Reorienting corporate strategy around stable dividend growth instead of pure enterprise value expansion.
[00:09:24] Portfolio Surgery – Using market attractiveness vs. competitive position to rebalance cyclicality and reshape capital allocation.
[00:10:26] The Adjacency Map Framework – Defining “right-to-win” expansion zones across technology, geography, business model, and customer verticals.
[00:13:38] Tollgates Before IOI – Aligning board approval and capital allocation early to enter deals with conviction and certainty.
[00:15:56] Day Two Strategy Integration – Building 7-year strategic plans with acquired teams to create solution co-ownership post-close.
[00:21:07] Soft vs. Hard Synergies – Prioritizing growth conviction and scalable models over traditional cost-cutting synergies.
[00:30:27] Winning with Emotional Alignment – Provoking sellers with vision-led conversations that secure management support—even without the highest bid.
[00:38:09] Four Questions Behind a Billion-Dollar Deal – Testing technology defensibility, customer concentration risk, growth durability, and talent retention.
[00:45:37] Capital Allocation Battles – How M&A competes with organic investments across 20 SBUs and dozens of profit centers.
[00:51:16] Customer Awareness as Risk Control – Using third-party market interviews to prevent post-close revenue surprises.
[00:58:50] The Craziest Thing in M&A – An 11th-hour closing crisis triggered by a messy divorce and disputed property title nearly derailing the deal